title: Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
abstract: Aims: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) compared with the durable polymer PROMUS Element (PE) EES. The current analysis describes the six-month IVUS and clinical results through two years from the EVOLVE FHU trial. Methods and results: EVOLVE recruited 291 patients from 29 centres. At six months, IVUS-assessed in-stent net volume obstruction was 3.40±5.06% for PROMUS Element (PE) vs. 2.68±4.60% for SYNERGY (p=0.34) and 3.09±4.29% for SYNERGY ½ dose (p=0.68 vs. PE). There were no significant differences between groups for any other measured IVUS parameter including resolved, persistent, and late-acquired incomplete stent apposition (ISA). At two years, target lesion failure (TLF) was 6.1% for PE vs. 5.5% for SYNERGY (p=0.87) and 5.2% for SYNERGY ½ dose (p=0.81). There were no significant differences between groups for cardiac death, repeat revascularisation, MI or stent thrombosis through two years. Conclusions: At six months, everolimus delivered from an ultrathin bioabsorbable abluminal polymer resulted in equivalent net volume obstruction and ISA compared with a permanent polymer EES. There were no significant differences between PE and either SYNERGY stent for any major cardiac endpoint through two years. Clinical trials number: NCT01135225.
authors.affiliation: MonashHeart, Clayton, Victoria, Australia.
authors.forename: Ian T
authors.initials: IT
authors.lastname: Meredith
authors.forename: Stefan
authors.initials: S
authors.lastname: Verheye
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Weissman
authors.forename: Paul
authors.initials: P
authors.lastname: Barragan
authors.forename: Douglas
authors.initials: D
authors.lastname: Scott
authors.forename: Mariano Valdés
authors.initials: MV
authors.lastname: Chávarri
authors.forename: Nick E J
authors.initials: NE
authors.lastname: West
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbæk
authors.forename: Robert
authors.initials: R
authors.lastname: Whitbourn
authors.forename: Darren L
authors.initials: DL
authors.lastname: Walters
authors.forename: Jacek
authors.initials: J
authors.lastname: Kubica
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Monica
authors.initials: M
authors.lastname: Masotti
authors.forename: Adrian
authors.initials: A
authors.lastname: Banning
authors.forename: Iwar
authors.initials: I
authors.lastname: Sjögren
authors.forename: Rod H
authors.initials: RH
authors.lastname: Stables
authors.forename: Dominic J
authors.initials: DJ
authors.lastname: Allocco
authors.forename: Keith D
authors.initials: KD
authors.lastname: Dawkins